Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Concord Healthcare Group Co., Ltd. Class H ( (HK:2453) ) has provided an announcement.
Concord Healthcare Group Co., Ltd. announced that its subsidiary, Guangzhou Concord Cancer Center, has been approved to be included in the list of designated medical institutions under the Measure of Using Hong Kong Registered Drugs and Medical Devices in the Guangdong-Hong Kong-Macao Greater Bay Area. This approval allows the company to import and utilize advanced oncology drugs and medical devices from Hong Kong and Macau, which are not yet available in Mainland China. This strategic move is expected to expand the company’s business scope, enhance its competitive advantage in oncology healthcare, and improve cancer treatment standards by integrating international medical resources.
The most recent analyst rating on (HK:2453) stock is a Sell with a HK$2.00 price target. To see the full list of analyst forecasts on Concord Healthcare Group Co., Ltd. Class H stock, see the HK:2453 Stock Forecast page.
More about Concord Healthcare Group Co., Ltd. Class H
Concord Healthcare Group Co., Ltd. is a joint stock company based in the People’s Republic of China, specializing in oncology healthcare. The company focuses on providing innovative cancer treatment solutions and is involved in the integration of advanced medical resources from Hong Kong and Macau.
Average Trading Volume: 1,176,714
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.48B
For an in-depth examination of 2453 stock, go to TipRanks’ Overview page.